Compare the efficacy and pharmacokinetic characteristics of levosimendan of two methods of administration in elderly patients with heart failure

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-14005584

Enrollment

Unknown

Registered

2014-11-29

Start date

2014-10-07

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure

Interventions

A:Maintenance dose of levosimendan

B:loading dose of Levosimendan

Eligibility

Sex/Gender

All

Age

75 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Aged to be older than 75 years, male or female; 2. consistent with acute heart failure diagnostic criteria; 3. required inotropic applications; 4. voluntary or the legally authorized person agrees to participate in this study, and written informed consent; 5. without any other factors which impact to participate the clinical trial.

Exclusion criteria

Exclusion criteria: 1. severe disfunction in liver (ChildB or C grade), kidney (creatinine clearance less than 30ml/min); 2. cardiac mechanical obstruction significantly affect the ventricular filling and / or ejection fraction; 3. patients with severe hypotension or tachycardia (heart rate more than 140 beats/min); 4. patients with history of torsades ventricular tachycardia (TdP); 5. patients allergic to levosimendan; 6. mental illness; 7. thyroid disease induced heart failure.

Design outcomes

Primary

Measure	Time frame
Concentration of OR-1896;Hemodynamic parameter;Ultrasound evaluation;	—

Secondary

Measure	Time frame
Biomarkers;ECG;	—

Countries

China

Contacts

Public ContactYan Jing

zjicu@vip.163.com+86 13336188688

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026